Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ESRRA Biologics Sequence Review Report 2026: Steroid hormone receptor ERR1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ESRRA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ESAM Biologics Sequence Review Report 2026: Endothelial cell-selective adhesion molecule Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ESAM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EPS8L3 Biologics Sequence Review Report 2026: Epidermal growth factor receptor kinase substrate 8-like protein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EPS8L3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EPS8L2 Biologics Sequence Review Report 2026: Epidermal growth factor receptor kinase substrate 8-like protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EPS8L2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EPS8L1 Biologics Sequence Review Report 2026: Epidermal growth factor receptor kinase substrate 8-like protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EPS8L1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EPS8 Biologics Sequence Review Report 2026: Epidermal growth factor receptor kinase substrate 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EPS8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EGFL8 Biologics Sequence Review Report 2026: Epidermal growth factor-like protein 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EGFL8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EGFL6 Biologics Sequence Review Report 2026: Epidermal growth factor-like protein 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EGFL6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EGF Biologics Sequence Review Report 2026: Pro-epidermal growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of EGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DSCAML1 Biologics Sequence Review Report 2026: Cell adhesion molecule DSCAML1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of DSCAML1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DOCK3 Biologics Sequence Review Report 2026: Dedicator of cytokinesis protein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of DOCK3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CYTL1 Biologics Sequence Review Report 2026: Cytokine-like protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CYTL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.